Recordati Industria Chimica E Farmaceutica (RCDTF) Expected to Announce Quarterly Earnings on Thursday

Posted by Donald Scott on Mar 17th, 2026

Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF – Get Free Report) is expected to post its resultson Thursday, March 19th. Analysts expect Recordati Industria Chimica E Farmaceutica to post earnings of $0.8570 per share and revenue of $769.7510 million for the quarter.

Recordati Industria Chimica E Farmaceutica Stock Performance

Shares of OTCMKTS:RCDTF opened at $56.95 on Tuesday. The firm has a fifty day simple moving average of $63.06 and a two-hundred day simple moving average of $64.60. Recordati Industria Chimica E Farmaceutica has a 52 week low of $49.00 and a 52 week high of $65.44. The company has a quick ratio of 1.16, a current ratio of 1.64 and a debt-to-equity ratio of 1.13. The stock has a market capitalization of $11.75 billion, a P/E ratio of 16.90 and a beta of 0.28.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on RCDTF. Barclays raised shares of Recordati Industria Chimica E Farmaceutica from a “strong sell” rating to a “hold” rating in a report on Thursday, February 12th. Kepler Capital Markets upgraded Recordati Industria Chimica E Farmaceutica from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, February 3rd. Two equities research analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy”.

Get Our Latest Stock Analysis on Recordati Industria Chimica E Farmaceutica

Recordati Industria Chimica E Farmaceutica Company Profile

(Get Free Report)

Recordati Industria Chimica e Farmaceutica is an Italy‐based international pharmaceutical company engaged in the research, development, manufacturing and commercialization of therapeutic products. Established in 1926, the company has built a diversified portfolio that includes proprietary drugs, generics and orphan medicines, with a particular emphasis on treatments for rare diseases. Recordati’s product range spans cardiovascular, urology, endocrinology, dermatology and oncology therapies, as well as specialized formulations for genetic and metabolic disorders.

The company’s historical roots date back nearly a century, when it began as a family‐owned enterprise in Milan.